JUNSHI BIO (01877): Toripalimab Receives Regular Approval from the National Medical Products Administration for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Platinum-Containing Chemotherapy

JUNSHI BIO (01877) announced that recently, the Company received the Drug Supplementary Application Approval Notice approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), approving the indication of toripalimab injection (trade name: TUOYI, product code: JS001) as a monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma that has failed platinum-containing chemotherapy, including disease progression within 12 months of neoadjuvant or adjuvant chemotherapy, to be converted from conditional approval to regular approval.